


Proceedings from Huntington's Disease Regulatory Science Consortium (HD-RSC) Kick-Off Meeting, Nov. 6-7, 2017

On November 6 and 7, 2017, in Silver Spring, MD, Critical Path Institute and CHDI Foundation welcomed participants from the pharmaceutical industry, academia, regulatory agencies, and advocacy groups to a kick-off meeting for the Huntington's Disease Regulatory Science Consortium (HD-RSC). The meeting objectives were to solicit input from stakeholders on HD-RSC plans and deliverables, and to develop an understanding of 1) the value of a pre-competitive consortium model to advance regulatory science and enable drug development in HD; 2) the critical importance of data contributions in advancing regulatory science, and for the success of HD-RSC.

 [Meeting Agenda](#)

 [The Vision: CHDI's Dedication to Successful HD Treatments \(R. Blumenstein\)](#)


 [Consortia-Based Strategies in Neurodegenerative Diseases:
Critical Path Institute's Track Record in Collaborative Efforts \(M. Brumfield\)](#)


 [Model Informed Drug Development \(I. Zineh\)](#)

 [From Model-Based Clinical Trial Enrichment to Comprehensive Clinical Trial Simulation \(B. Corrigan\)](#)


 [Success in Sharing Data from HD Natural History Studies \(A. Mohan\)](#)

 [Rationale and Impact of Building a Comprehensive HD Clinical Database \(C. Sampaio\)](#)

 [Biomarkers as Tools to Enable Decision-Making in HD Drug Development \(E. Siemers\)](#)

 [Clinical Outcome Measures in HD: Beyond UHDRS \(G. Stebbins\)](#)

 [The Operations: How HD-RSC Will Work \(D. Stephenson\)](#)

 [Critical Path to TB Drug Regimens: Global Collaboration for Accelerating Novel TB Regimen Development \(D. Hanna\)](#)

 [Presentation by Charles Sabine, Patient Advocate: "The Impact: Why This Matters to Patients"](#)

 [Meeting Bios](#)

 [Meeting Attendees](#)

 [Meeting Summary](#)